Clinical trials: Colorectal Tumors
Unresectable Metastatic Colorectal Cancer
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by…
- Trial name
- NCT04991948
- Testing
- CYAD-101, FOLFOX, Pembrolizumab
- Where
- 5 sites in United States, Belgium
- Volunteers
- 34 people
- Sponsor
- Celyad Oncology SA
Colon Cancer, Colorectal Cancer
Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
The primary objective is to estimate the effect of the human homolog of the Kirsten rat sarcoma-2 virus oncogene (KRAS) mutation status (wild type versus mutant) from tumor tissue on efficacy endpoints in patients with metastatic…
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer, Cancer
- Trial name
- PRECEPT (NCT00411450)
- Testing
- Panitumumab, FOLFIRI
- Volunteers
- 116 people
- Sponsor
- Amgen
Metastatic Colorectal Carcinoma
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI.
- Trial name
- NCT01937715
- Testing
- PF-05212384, FOLFIRI regimen, Bevacizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 18 people
- Sponsor
- Pfizer
Advanced Solid Tumors, Locally Advanced or Metastatic Breast or Colorectal Cancer
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
This is an open-label, multi-center, dose-finding study of tivozanib administered in combination with capecitabine. During the dose-escalation portion, sequential cohorts of subjects with advanced solid tumors will be enrolled in…
- Trial name
- NCT01306630
- Testing
- tivozanib (AV-951) and capecitabine (Xeloda®)
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Genital Warts, Anal Cancer
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
This study is designed to evaluate the immunogenicity and tolerability of 9vHPV (9-valent HPV vaccine, V503) in 16- to 26-year old men and women.
- Conditions
- Genital Warts, Anal Cancer, Anal Intraepithelial Neoplasia
- Trial name
- NCT01651949
- Testing
- 9vHPV Vaccine
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer
This study dynamically monitored the prognosis of stage I-IV colorectal cancer patients who could receive radical surgical resection by detecting the levels of polygene methylation in plasma samples from patients with colorectal…
- Trial name
- NCT05444491
- Where
- 7 sites in China
- Volunteers
- 800 people
- Sponsor
- Singlera Genomics Inc.
Advanced Solid Tumors, Colorectal Cancer
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer, Biliary Tract Cancer
- Trial name
- NCT05116891
- Testing
- CAN04 (nadunolimab), mFOLFOX, DTX
- Where
- 6 sites in France, Spain
- Volunteers
- 40 people
- Sponsor
- Cantargia AB
Colorectal Cancer
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
The purpose of this clinical trial is to determine whether the combination of 5-fluorouracil (5-FU) plus a DAVANAT (carbohydrate polymer) along with Avastin and Leucovorin (LV) is beneficial in treating colorectal cancer in…
- Trial name
- NCT00388700
- Testing
- GM-CT-01, 5-Fluorouracil, Leukovorin, bevacizumab
- Where
- 4 sites in Israel
- Sponsor
- Galectin Therapeutics Inc.
Ovarian Cancer, Fallopian Tube Cancer
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- COTI2-101 (NCT02433626)
- Testing
- COTI2, Cisplatin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Critical Outcome Technologies Inc.
Colorectal Cancer; Lung Cancer
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
- Trial name
- NCT04701476
- Testing
- TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 110 people
- Sponsor
- Teclison Ltd.
Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies.
- Trial name
- HERKULES-3 (NCT05039177)
- Testing
- ERAS-007, Encorafenib, Cetuximab
- Where
- 14 sites in United States
- Volunteers
- 101 people
- Sponsor
- Erasca, Inc.
Advanced Solid Tumors, Carcinoid
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease…
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced
- Trial name
- NCT01327612
- Testing
- Modified FOLFOX6, Conatumumab, Ganitumab
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 12 people
- Sponsor
- Amgen
Colorectal Cancer, Anastomosis
Safe Anastomosis Feasibility Study
A clinical trial to assess the efficacy, mechanism of action and safety of the Colovac+ Colorectal Anastomosis Protection Device in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection…
- Trial name
- SAFE2019 (NCT05180565)
- Testing
- Colovac
- Where
- 7 sites in Belgium, France
- Volunteers
- 27 people
- Sponsor
- SafeHeal Inc
Colorectal Cancer, Colorectal Polyp
Feasibility and Safety of MiWEndo-assisted Colonoscopy
The study involves the planned use of a new microwave-based device during colonoscopy procedures in a small group of patients to assess the preliminary safety of its use and lack of normal clinical practice modification.
- Conditions
- Colorectal Cancer, Colorectal Polyp, Colorectal Adenoma, Colorectal Neoplasms
- Trial name
- MiWEndo1 (NCT05477836)
- Testing
- MiWEndo-assisted colonoscopy
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- MiWEndo Solutions S.L.
Colorectal Cancer
An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin
The overall purpose of this study is to determine the efficacy, safety and tolerability of indisulam in combination with irinotecan as a treatment for patients with metastatic colorectalcancer previously treated with…
- Trial name
- NCT00165867
- Testing
- E7070
- Where
- 7 sites in France, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Eisai Limited
Colorectal Cancer
Evaluation of CG-100 Intraluminal Bypass Device
Evaluation of CG-100 Intraluminal Bypass device
- Trial name
- NCT05632744
- Testing
- CG-100 Intraluminal Bypass Device
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- Colospan Ltd.
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- innovaTV 207 (NCT03485209)
- Testing
- tisotumab vedotin, pembrolizumab, carboplatin
- Where
- 175 sites in United States, Canada and 5 more
- Volunteers
- 350 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Metastatic Colorectal Cancer
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant…
- Trial name
- NCT05743036
- Testing
- ZN-c3, Encorafenib, Cetuximab
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 44 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.